08 January 2025
Zoom
Draft Agenda
The meeting will take place as a meeting via Zoom, a secure web conferencing tool.
This meeting will run from 9:00am to 5:00pm, although timings may be subject to change.
Please note that this agenda is a draft and is subject to change before the meeting.
- Welcome and introduction to format of meeting –Part 2 only (closed session)
- Apologies - Part 2 only (closed session)
- Any other business – Part 2 only (closed session)
- Minutes from the last meeting held on 12 December 2024 – Part 2 only (closed session)
- Appraisal of Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
5.1. Introduction by the Chair, Dr Charles Crawley - Part 2 only (closed session)
5.2. Declaration of interests - Part 2 only (closed session)
5.3. Presentation by the lead team - Part 2 only ( closed session)
5.4. Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG) - Part 2 only (closed session)
Belantamab mafodotin with bortezomib and dexamethasone has not yet received regulatory approval so this committee discussion will be held in private
- Appraisal of Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
- Appraisal of Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6211]]
6.1. Introduction by the Chair, Dr Charles Crawley - Part 2 only (closed session)
6.2. Declaration of interests - Part 2 only (closed session)
6.3. Presentation by the lead team - Part 2 only (closed session)
6.4. Agreement on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG) - Part 2 only (closed session)
Belantamab mafodotin with pomalidomide and dexamethasone has not yet received regulatory approval so this committee discussion will be held in private
To print this agenda, please right click and select ‘Print’ from the menu.
Important information about this meeting:
Belantamab mafodotin with bortezomib and dexamethasone and Belantamab mafodotin with pomalidomide and dexamethasone have not yet received regulatory approval so these committee discussions will be held in private.
Should you have any queries regarding observing this meeting, please contact Leah Murphy.
- Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
Date and time of next meeting
The next meeting will take place on Wednesday 5 February 2025 at 9am via Zoom.
Please note all timings are approximate.